Piper Sandler Maintains Overweight on Revolution Medicines, Raises Price Target to $172
Revolution Medicines
Revolution Medicines RVMD | 0.00 |
Piper Sandler analyst Kelsey Goodwin maintains Revolution Medicines (NASDAQ:
RVMD) with a Overweight and raises the price target from $120 to $172.
